Emerging data suggest Retatru tide , a dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide , appears to offer a significant step forward for weight treatment. Initial clinical investigations have indicated impressive reductions in visceral mass , potentially surpassing other weight-loss treatments. Nevertheless , addi